Table E3.
Patient | Refresh Tears 1:100 (intradermal), mm (wheal flare) | Refresh Tears 1:10 (intradermal), mm (wheal ×flare) |
---|---|---|
1 | 10 × 20 | — |
2 | 0 | 7 × 15 |
3 | 0 | 8 × 18 |
4 | 0 | 0 |
5 | 8 × 18 | — |
6 | 9 × 14 | — |
7 | 0 | 0 |
8 | 0 | 0 |
9 | 0 | 0 |
10 | 0 | 0 |
11 | 8 × 13 | — |
12 | 0 | 0 |
13 | 9 × 20 | — |
14 | 0 | 7 × 18 |
15 | 0 | 0 |
16 | 0 | — |
17 | 0 | — |
18 | 0 | 6 × 24 |
19 | 0 | 0 |
20 | 0 | 0 |
21 | 0 | 0 |
22 | 8 × 18 | — |
23 | 7 × 8 | — |
24 | 0 | 4 × 8 |
25 | 5 × 10 | — |
Total | 8 (32%) | 5 (20%) |
Among 25 nonallergic controls, there were 13 positive reactions (52%) to Refresh Tears on intradermal testing, with 8 positive at the 1:100 concentration (32%) and 5 positive at the 1:10 concentration (20%).